Assessment of P2Y₁₂ inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

VerifyNow PRUs after administration of prasugrel 60 mg LD/10 mg MD and clopidogrel 600 mg LD/75 mg MD. ■ represents prasugrel; ▲, clopidogrel.

Association of percent inhibition reported by VerifyNow P2Y12 and calculated percent inhibition with PRU at baseline (predose). Correlation coefficient (r) was calculated by Lin's concordance method. ■ represents prasugrel; ▲, clopidogrel; filled line, unity line.

Association between PRU from VN-P2Y12 and percent PRI from VASP after prasugrel and clopidogrel LD (A) and MD (B) regimens. Symbols represent individual simultaneous measurements at baseline, 2 hours, and 24 hours after LD and at predose at days 14 and 29. Correlation coefficients (r) were calculated by the Pearson method. ■ represents prasugrel; ▲, clopidogrel.

Association between PRU from VN-P2Y12 and RPA from LTA induced with 20 μmol/L ADP after prasugrel and clopidogrel LD (A) and MD (B) regimens. Symbols represent individual simultaneous measurements at baseline, 2 hours, and 24 hours after LD and at predose at days 14 and 29. Correlation coefficients (r) were calculated by the Pearson method. ■ represents prasugrel; ▲, clopidogrel.

Scatter plot of PRU from VN-P2Y12 versus AUC (μmol/L · h) of active metabolite of prasugrel and clopidogrel. A, During prasugrel and clopidogrel LD regimens with AUC determined over the 24 hours post-LD. B, During prasugrel and clopidogrel MD. Correlation coefficients (r) were calculated by the Pearson method. ■ represents prasugrel; ▲, clopidogrel.